St. Jude Children's Research Hospital Completes Phase 2 Clinical Trial of Memantine for Preventing Cognitive Decline in Pediatric Brain Tumor Patients Undergoing Radiation Therapy
A First Step Towards Addressing the Devastating Cognitive Side Effects of Radiation Therapy in Pediatric Brain Tumors
Children with pediatric brain tumors undergo cranial radiotherapy, which is essential for removing tumors but can cause permanent brain tissue damage. Cognitive late effects, such as significant declines in attention, working memory, and learning speed, are a major unmet medical need that hinders academic and daily life. The Phase 2 clinical trial (MEMCRT, NCT03194906) led by St. Jude Children's Research Hospital is significant as it represents the first attempt to pharmacologically prevent this neurological decline.
Memantine's Mechanism of Action and Drug Repurposing Strategy
The drug used in this study, Memantine Hydrochloride (brand name Namenda®), is an NMDA receptor antagonist widely used in adults with moderate-to-severe Alzheimer's disease. Memantine works by blocking excitotoxicity and neuronal death that occur immediately after radiation exposure, protecting normal brain tissue. By adopting a drug repurposing strategy, which involves finding new uses for existing compounds with established safety profiles, the researchers have created a pathway to accelerate clinical development and reduce costs.
High Feasibility and Adherence Data in Pediatric Patients
In this pilot trial, which randomized a total of 34 pediatric patients, the researchers focused on demonstrating feasibility and adherence. The results showed that the memantine treatment group had a medication adherence rate of 93.75% (90% CI: 73.6% to 99.68%), and the completion rate for at least three cognitive assessments was 100%, demonstrating high feasibility even during aggressive cancer treatment. The safety assessment (SAFTEE) also showed no significant differences in adverse events compared to the placebo group, further solidifying the safety profile in pediatric patients.
Primary Efficacy Endpoints Demonstrating Improved Cognitive Function and Quality of Life
Exploratory efficacy analyses showed that the memantine group exhibited positive trends in several cognitive function scores, including attention speed and academic fluency, at 12 weeks compared to the control group. In particular, the quality of life scores, assessed using the Pediatric Fatigue Scale (PedsQL MDFS), showed a significant improvement in fatigue at 12 weeks, with a Cohen's d of 0.72 (90% CI: 0.05 to 1.4), suggesting the potential to improve the quality of life for these patients. Although the statistical difference narrowed at the 1-year follow-up (Cohen's d -0.13), the value of memantine as a prophylactic agent to prevent severe cognitive decline immediately after treatment is still significant.
The completion of this Phase 2 clinical trial by St. Jude's is a significant milestone in rediscovering the commercial value of memantine as the first pharmacological option for preventing side effects from radiation therapy in pediatric brain tumors. In the U.S. market, where approximately 4,000 new cases of pediatric brain tumors are diagnosed annually, the lack of a standard treatment for preventing radiation-induced side effects increases the potential for memantine to gain exclusive market access. Unlike existing cognitive impairment treatments such as Methylphenidate (Ritalin®) or Donepezil (Aricept®), which are administered after the onset of symptoms, memantine's mechanism of action, which involves administration during treatment, provides a strong competitive advantage in capturing early prescription demand. Although the pediatric brain tumor market is a rare disease, considering the potential for expansion to the adult brain metastasis and head and neck cancer radiation therapy market, which is estimated at $4.5 billion annually, memantine has significant long-term value as a platform technology. Upon final approval through a confirmatory Phase 3 trial, it is expected to become a representative success story of a low-cost, high-efficiency drug repurposing business model.
Source: ClinicalTrials.gov (api_ct)